- Risk of bDMARD withdrawal higher for TNFi monotherapy compared w/ cs/bDMARD combination - If monotherapy necessary, etanercept should be preferred over infliximab and adalimumab Silvagni E et al. BMJ Open 2018 #ACR19 @RheumNow